<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02827617</url>
  </required_header>
  <id_info>
    <org_study_id>IOSI-EMA-001</org_study_id>
    <nct_id>NCT02827617</nct_id>
  </id_info>
  <brief_title>Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Prospective, Observational, Multi-centred, Non-interventional Study on the Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncology Institute of Southern Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncology Institute of Southern Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general aim of the project is the identification of dynamic molecular markers that can
      help the early and real time prediction of sustained benefit or no benefit from ibrutinib
      treatment in CLL harboring TP53 mutations. Specific aims of the project include: 1) Assess
      whether clearance of TP53 mutated clones translates into a predictive biomarker of long term
      benefit from ibrutinib treatment in CLL. 2) Assess whether plasma cell free DNA represents a
      sensitive tool that can early and dynamically inform on the development of ibrutinib
      resistant mutations in CLL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the chemoimmunotherapy era, TP53 mutations defined a subgroup of high risk chronic
      lymphocytic leukemia (CLL) patients in whom allogeneic stem cell transplantation had to be
      strongly considered. As a result of the accumulating favorable outcome data reported for new
      biological drugs, including ibrutinib, in high risk CLL harboring TP53 mutations, there is
      concern about whether these patients should continue to be offered allogeneic stem cell
      transplantation. Despite their improved outcome, a proportion of high risk CLL harboring TP53
      mutations is going to develop ibrutinib resistance, which in turns translate in a very poor
      survival. On these bases, in the setting of ibrutinib treatment, novel biomarkers are
      required to re-define high risk CLL patients candidate for consolidation strategies including
      allogeneic stem cell transplantation. Our working hypotheses are that: i) clearance of high
      risk TP53 mutated clones upon treatment with ibrutinib may associate with long progression
      free survival (PFS), while conversely, the persistence or increase of high risk TP53 mutated
      subclones under ibrutinib may associate with acquisition of resistance and disease
      progression; and ii) plasma cell free DNA represents an accessible source of tumor DNA for
      the early and sensitive identification of mutations causing resistance to ibrutinib. By using
      highly sensitive ultra-deep next generation sequencing strategies to monitor molecular
      biomarkers potentially relevant for ibrutinib in DNA coming from both cellular and the plasma
      fractions of peripheral blood, the project has the chance of identifying new dynamic
      molecular markers that can help the early and real time prediction of sustained benefit from
      ibrutinib treatment vs imminent progression in TP53 mutated CLL patients. In the end, the
      results of this study will provide the bases to refine the current approach for treatment
      tailoring in TP53 mutated patients by allowing the identification of cases who, though being
      in clinical response under ibrutinib, will conceivably benefit from immediate switch to
      alternative options (i.e. novel drugs, allogeneic stem cell transplantation, or CART).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of clonal response on PFS</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the impact of clonal response (namely clearance of TP53 mutated alleles in the peripheral blood (PB) CLL cells at Week 24 after treatment start) on PFS measured according to iwCLL guidelines (Hallek 2008) as the interval from ibrutinib treatment start to progression (event), death (event) or last follow-up (censoring). Progression will be defined as per investigator assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of clonal response at Week 24 after treatment start</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the proportion of clonal response, defined as clearance (100% reduction compared to baseline) of TP53 mutated alleles in the PB CLL cells at Week 24 after treatment start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative proportion of clonal response</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the cumulative proportion of clonal response, defined as clearance (100% reduction compared to baseline) of TP53 mutated alleles in the PB CLL cells at any time from treatment start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of clonal response on overall survival</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the impact of clonal response on overall survival (OS) measured according to iwCLL guidelines (Hallek 2008) as the interval from ibrutinib treatment start to death (event) or last follow-up (censoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of clonal response on the cumulative incidence of acquisition of resistance-mutations</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the effect of clonal response on the cumulative incidence of acquisition of resistance-mutations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect clonal response on the cumulative incidence of transformation to Richter syndrome</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the effect of clonal response on the cumulative incidence of transformation to Richter syndrome defined as the interval between ibrutinib treatment start to histologically documented development of an aggressive lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of treatment-emergent BTK and PLCγ2 resistance mutations on PFS</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the impact of treatment-emergent BTK and PLCγ2 resistance mutations on PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of treatment-emergent BTK and PLCγ2 resistance mutations on OS</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the impact of treatment-emergent BTK and PLCγ2 resistance mutations on OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of treatment-emergent BTK and PLCγ2 resistance mutations on the cumulative incidence of transformation to Richter syndrome</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the impact of treatment-emergent BTK and PLCγ2 resistance mutations on the cumulative incidence of transformation to Richter syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of plasma cell free DNA for the identification of BTK and PLCγ2 resistance mutations</measure>
    <time_frame>2/2016-2/2021</time_frame>
    <description>To evaluate the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of plasma cell free DNA vs tumor genomic DNA genotyping for the identification of BTK and PLCγ2 resistance mutations</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>TP53 mutated CLL</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Treatment with ibrutinib 420 mg quaque die in the clinical practice</description>
    <arm_group_label>TP53 mutated CLL</arm_group_label>
    <other_name>PCI-32765</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor periphral blood cells, Plasma, Tumor genomic DNA, Plasma cell free DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult CLL patients harboring TP53 genetic abnormalities, independent of whether treatment
        naïve or previously treated, who warrants treatment according to iwCLL 2008 criteria, and
        who is planned to receive ibrutinib at standard dose as per clinical practice
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults 18 years or older

          -  Documented diagnosis of CLL, according to iwCLL 2008 criteria

          -  Presence of TP53 mutation as demonstrated by sequencing at the local laboratory and/or
             presence of 17p deletion as demonstrated by fluorescence in situ hybridization (FISH)
             testing performed at the local laboratory

          -  CLL that warrants treatment

          -  Planned treatment with ibrutinib 420 mg quaque die

          -  Willing and able to comply with scheduled visits, laboratory tests, and study
             procedures

          -  Evidence of a signed informed consent

        Exclusion Criteria:

          -  Current or prior histological transformation from CLL to an aggressive lymphoma (ie,
             Richter transformation).

          -  Prior treatment with ibrutinib or idelalisib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davide Rossi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Institute of Southern Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davide Rossi, MD, PhD</last_name>
    <phone>0041 (0)918118540</phone>
    <email>davide.rossi@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatiana Terrrot</last_name>
    <phone>0041 (0)918119183</phone>
    <email>tatiana.terrot@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onco Ematologia Clinico Sperimentale, I.R.C.C.S. Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pietro Bulian, MD</last_name>
      <email>pbulian@cro.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Ghia, MD</last_name>
      <phone>+39 02 26434797</phone>
      <email>ghia.paolo@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Eloise Scarano</last_name>
      <phone>+39 02 2643 3919</phone>
      <email>scarano.eloise@hsr.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Ematologia, Niguarda Cancer Center, Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Tedeschi, MD</last_name>
      <phone>+39 02 64442668</phone>
      <email>alessandra.tedeschi@ospedaleniguarda.it</email>
    </contact>
    <contact_backup>
      <last_name>Stefana Brusorio</last_name>
      <phone>+39 02 64447597</phone>
      <email>stefania.brusorio@ospedaleniguarda.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Medical and Surgical Sciences, section of Hematology</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Marasca, MD</last_name>
      <phone>+39 059 4225473</phone>
      <email>roberto.marasca@unimore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Universita' del Piemonte Orientale</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano, MD</last_name>
      <phone>+39 0321 660655</phone>
      <email>gianluca.gaidano@med.uniupo.it</email>
    </contact>
    <contact_backup>
      <last_name>Clara Deambrogi</last_name>
      <phone>+39 0321 3732194</phone>
      <email>clara.deambrogi@med.uniupo.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology, Catholic University S. Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Laurenti, MD</last_name>
      <email>l.laurenti@rm.unicatt.it</email>
    </contact>
    <contact_backup>
      <last_name>Simona Sica</last_name>
      <email>Simona.Sica@unicatt.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Tor Vergata Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Del Poeta, MD</last_name>
      <phone>+39 0620903407</phone>
      <email>g.delpoeta@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica, Centro Trapianti e Terapie Cellulari &quot;Carlo Melzi&quot;</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Zaja, MD</last_name>
      <phone>+ 39 0432 559604</phone>
      <email>francesco.zaja@asuiud.sanita.fvg.it</email>
    </contact>
    <contact_backup>
      <last_name>Cristina D'Odorico</last_name>
      <email>cristina.dodorico@asuiud.sanita.fvg.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ematologia, Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Passamonti, MD</last_name>
      <phone>+39 0332 393648</phone>
      <email>francesco.passamonti@ospedale.varese.it</email>
    </contact>
    <contact_backup>
      <last_name>Michele Merli</last_name>
      <phone>+39 0332 278848</phone>
      <email>michele.merli@asst-settelaghi.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Division of Hematology, Department of Internal Medicine, Basel University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakob Passweg, MD</last_name>
      <phone>+41 (0)61 328 7277</phone>
      <email>jakob.passweg@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Sylvia Villa</last_name>
      <phone>+41 (0)61 265 55 21</phone>
      <email>HaemResearch@usb.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Rossi, MD, PhD</last_name>
      <phone>0041 (0)91 811 8540</phone>
      <email>davide.rossi@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Tatiana Terrot</last_name>
      <phone>0041 (0)91 811 9183</phone>
      <email>tatiana.terrot@eoc.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Davide Rossi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology, Luzern Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gregor, MD</last_name>
      <phone>+41 (0)41 205 5147</phone>
      <email>michael.gregor@luks.ch</email>
    </contact>
    <contact_backup>
      <last_name>Gaby Fahrni</last_name>
      <phone>+41 (0) 41 205 1803</phone>
      <email>gaby.fahrni@luks.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oncology Institute of Southern Switzerland</investigator_affiliation>
    <investigator_full_name>Davide Rossi</investigator_full_name>
    <investigator_title>Sponsor, Project Leader and Coordinating researcher</investigator_title>
  </responsible_party>
  <keyword>Ibrutinib</keyword>
  <keyword>TP53</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

